Regulation of glycosaminoglycan structure and atherogenesis

Cellular and Molecular Life Sciences

Volumn 61, Issue 11, 2004, Pages 1296-1306

  Ballinger, M L ^a,b   Nigro, J ^a,b   Frontanilla, K V ^a   Dart, A M ^a,b   Little, P J ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Atherosclerosis; Elongation; Glycosaminoglycans; Lipoprotein; Proteoglycans; Sulfation, epimerisation

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; 2,4 THIAZOLIDINEDIONE DERIVATIVE; AMLODIPINE; BIGLYCAN; CALCIUM ANTAGONIST; CERIVASTATIN; CHONDROITIN SULFATE; DARGLITAZONE; DECORIN; DERMATAN SULFATE; ENOXAPARIN; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLYCOSAMINOGLYCAN; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KERATAN SULFATE; LIPOPROTEIN; LIPOPROTEIN LIPASE; MIMECAN; NIFEDIPINE; PERLECAN; PROTEOHEPARAN SULFATE; SIMVASTATIN; SPHINGOMYELIN PHOSPHODIESTERASE; TROGLITAZONE; VERSICAN;

ATHEROGENESIS; BINDING AFFINITY; CARBOHYDRATE ANALYSIS; CARBOHYDRATE SYNTHESIS; CARBOXYLATION; DRUG MECHANISM; EPIMERIZATION; GEL MOBILITY SHIFT ASSAY; GOLGI COMPLEX; HUMAN; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN METABOLISM; MOLECULAR INTERACTION; NONHUMAN; PH MEASUREMENT; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SULFATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; GLYCOSAMINOGLYCANS; HUMANS; LIPOPROTEINS, LDL;

EID: 3042606559     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-004-3389-4     Document Type: Review

References (49)

1. Mokdad A. H., Ford E. S., Bowman B. A., Dietz W. H., Vinicor F., Bales V. S. et al. (2003) Prevalence of obesity, diabetes and obesity-related health risk factors, 2001. J. Am. Med. Assoc. 289: 76-79
2. Staels B. (2002) Cardiovascular biology: a cholesterol tether. Nature 417: 699-701
3. Ross R. (1986) The pathogenesis of atherosclerosis. N. Engl. J. Med. 314: 488-500
4. Griendling K. K. and Alexander R. W. (1997) Oxidative stress and cardiovascular disease [editorial; comment]. Circulation 96: 3264-3265
5. Bobik A., Agrotis A., Kanellakis P., Dilley R., Krushinsky A., Smirnov V. et al. (1999) Distinct patterns of transforming growth factor-beta isoform and receptor expression in human atherosclerotic lesions. Colocalization implicates TGF-beta in fibrofatty lesion development. Circulation 99: 2883-2891
6. Skalen K., Gustafsson M., Rydberg E. K., Hulten L. M., Wiklund O., Innerarity T. L. et al. (2002) Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 417: 750-754
7. Camejo G. (1982) The interaction of lipids and lipoproteins with the intercellular matrix of arterial tissue: its possible role in atherogenesis. Adv. Lipid. Res. 19: 1-53
8. Williams K. J. and Tabas I. (1995) The response-to-retention hypothesis of early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 15: 551-561
9. Chait A. and Bierman E. (1994) Pathogenesis of macrovascular disease in diabetes. In: Joslin's Diabetes Mellitus, p. 648-664, Kahn C. R. and Weir G. C. (eds), Lea and Febiger, Philadelphia
10. Martin S. J., Reutelingsperger C. P., McGahon A. J., Rader J. A., van Schie R. C., LaFace D. M. et al. (1995) Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J. Exp. Med. 182: 1545-1556
11. Oorni K., Pentikainen M. O., Annila A. and Kovanen P. T. (1997) Oxidation of low density lipoprotein particles decreases their ability to bind to human aortic proteoglycans. Dependence on oxidative modification of the lysine residues. J. Biol. Chem. 272: 21303-21311
12. Chait A. and Wight T. N. (2000) Interaction of native and modified low-density lipoproteins with extracellular matrix. Curr. Opin. Lipidol. 11: 457-463
13. Boren J., Olin K., Lee I., Chait A., Wight T. N. and Innerarity T. L. (1998) Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding. J. Clin. Invest. 101: 2658-2664
14. Wiklund O., Bondjers G., Wright I. and Camejo G. (1996) Insoluble complex formation between LDL and arterial proteoglycans in relation to serum lipid levels and effects of lipid lowering drugs. Atherosclerosis 119: 57-67
15. Williams K. J. and Tabas I. (1998) The response-to-retention hypothesis of atherogenesis reinforced. Curr. Opin. Lipidol. 9: 471-474
16. Boren J., Gustafsson M., Skalen K., Flood C. and Innerarity T. L. (2000) Role of extracellular retention of low density lipoproteins in atherosclerosis. Curr. Opin. Lipidol. 11: 451-456
17. Iverius P. H. (1972) The interaction between human plasma lipoproteins and connective tissue glycosaminoglycans. J. Biol. Chem. 247: 2607-2613
18. Wight T. N. (1989) Cell biology of arterial proteoglycans. Arteriosclerosis 9: 1-20
19. Schonherr E., Jarvelainen H. T., Kinsella M. G., Sandell L. J. and Wight T. N. (1993) Platelet-derived growth factor and transforming growth factor-beta 1 differentially affect the synthesis of biglycan and decorin by monkey arterial smooth muscle cells. Arterioscler. Thromb. 13: 1026-1036
20. Schonherr E., Kinsella M. G. and Wight T. N. (1997) Genistein selectively inhibits platelet-derived growth factor-stimulated versican biosynthesis in monkey arterial smooth muscle cells. Arch. Biochem. Biophys. 339: 353-361
21. Little P. J., Tannock L., Olin K. L., Chait A. and Wight T. N. (2002) Proteoglycans synthesized by arterial smooth muscle cells in the presence of transforming growth factor-beta1 exhibit increased binding to LDLs. Arterioscler. Thromb. Vasc. Biol. 22: 55-60
22. Schwartz N. (2000) Biosynthesis and regulation of expression of proteoglycans. Front. Biosci. 5: D649-655
23. Malmstrom A. and Fransson L. A. (1975) Biosynthesis of dermatan sulfate. I. Formation of L-iduronic acid residues. J. Biol. Chem. 250: 3419-3425
24. Sambandam T., Baker J. R., Christner J. E. and Ekborg S. L. (1991) Specificity of the low density lipoprotein-glycosaminoglycan interaction. Arterioscler. Thromb. 11: 561-568
25. Greve H., Cully Z., Blumberg P. and Kresse H. (1988) Influence of chlorate on proteoglycan biosynthesis by cultured human fibroblasts. J. Biol. Chem. 263: 12886-12892
26. Chang M. Y., Potter-Perigo S., Tsoi C., Chait A. and Wight T. N. (2000) Oxidized low density lipoproteins regulate synthesis of monkey aortic smooth muscle cell proteoglycans that have enhanced native low density lipoprotein binding properties. J. Biol. Chem. 275: 4766-4773
27. Figueroa J. E. and Vijayagopal P. (2002) Angiotensin II stimulates synthesis of vascular smooth muscle cell proteoglycans with enhanced low density lipoprotein binding properties. Atherosclerosis 162: 261-268
28. Sakr S. W., Eddy R. J., Barth H., Wang F., Greenberg S., Maxfield F. R. et al. (2001) The uptake and degradation of matrix-bound lipoproteins by macrophages require an intact actin Cytoskeleton, Rho family GTPases, and myosin ATPase activity. J. Biol. Chem. 276: 37649-37658
29. Gigli M., Ghiselli G., Torri G., Naggi A. and Rizzo V. (1993) A comparative study of low-density lipoprotein interaction with glycosaminoglycans. Biochim. Biophys. Acta 1167: 211-217
30. Olsson U., Bondjers G. and Camejo G. (1999) Fatty acids modulate the composition of extracellular matrix in cultured human arterial smooth muscle cells by altering the expression of genes for proteoglycan core proteins. Diabetes 48: 616-622
31. Camejo G., Fager G., Rosengren B., Hurt-Camejo E. and Bondjers G. (1993) Binding of low density lipoproteins by proteoglycans synthesized by proliferating and quiescent human arterial smooth muscle cells. J. Biol. Chem. 268: 14131-14137
32. Tannock L., Little P. J., Wight T. N. and Chait A. (2002) Arterial smooth muscle cell proteoglycans synthesized in the presence of glucosamine demonstrate reduced binding to LDL. J. Lipid. Res. 43: 149-157
33. Olsson U., Ostergren-Lunden G. and Moses J. (2001) Glycosaminoglycan- lipoprotein interaction. Glycoconj. J. 18: 789-797
34. Vijayagopal P., Figueroa J. E., Fontenot J. D. and Glancy D. L. (1996) Isolation and characterization of a proteoglycan variant from human aorta exhibiting a marked affinity for low density lipoprotein and demonstration of its enhanced expression in atherosclerotic plaques. Atherosclerosis 127: 195-203
35. Bailey W. L., LaFleur D. W., Forrester J. S., Fagin J. A. and Sharifi B. G. (1994) Stimulation of rat vascular smooth muscle cell glycosaminoglycan production by angiotensin II. Atherosclerosis 111: 55-64
36. Shimizu-Hirota R., Sasamura H., Mifune M., Nakaya H., Kuroda M., Hayashi M. et al. (2001) Regulation of vascular proteoglycan synthesis by angiotensin II type 1 and type 2 receptors. J. Am. Soc. Nephrol. 12: 2609-2615
37. Schonherr E., Jarvelainen H. T., Sandell L. J. and Wight T. N. (1991) Effects of platelet-derived growth factor and transforming growth factor-beta 1 on the synthesis of a large versican-like chondroitin sulfate proteoglycan by arterial smooth muscle cells. J. Biol. Chem. 266: 17640-17647
38. Blume-Jensen P. and Hunter T. (2001) Oncogenic kinase signalling. Nature 411: 355-365
39. Toma L., Pinhal M. A., Dietrich C. P., Nader H. B. and Hirschberg C. B. (1996) Transport of UDP-galactose into the Golgi lumen regulates the biosynthesis of proteoglycans. J. Biol. Chem. 271: 3897-3901
40. Ross R. (1999) Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340: 115-126
41. Vijayagopal P. and Subramaniam P. (2001) Effect of calcium channel blockers on proteoglycan synthesis by vascular smooth muscle cells and low density lipoprotein-proteoglycan interaction. Atherosclerosis 157: 353-360
42. Neal B., MacMahon S. and Chapman N. (2000) Effects of ACE inhibitors, calcium antagonists and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 356: 1955-1964
43. Nigro J., Dilley R. J. and Little P. J. (2002) Differential effects of gemfibrozil on migration, proliferation and proteoglycan production in human vascular smooth muscle cells. Atherosclerosis 162: 119-129
44. Tannock L. R., Little P. J., Barrett H. B., Wight T. N. and Chait A. Thiazolidinediones reduce the LDL binding affinity of non-human primate vascular cell proteoglycans. Diabetologia, in press
45. Meyers C. D., Tannock L. R., Wight T. N. and Chait A. (2003) Statin-exposed vascular smooth muscle cells secrete proteoglycans with decreased binding affinity for LDL. J. Lipid. Res. 44: 2152-2160
46. Richy F., Bruyere O., Ethgen O., Cucherat M., Henrotin Y. and Reginster J. Y. (2003) Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch. Intern. Med. 163: 1514-1522
47. Vijayagopal P., Srinivasan S. R., Radhakrishnamurthy B. and Berenson G. S. (1981) Interaction of serum lipoproteins and a proteoglycan from bovine aorta. J. Biol. Chem. 256: 8234-8241
48. Edwards I. J. and Wagner W. D. (1988) Distinct synthetic and structural characteristics of proteoglycans produced by cultured artery smooth muscle cells of atherosclerosis-susceptible pigeons. J. Biol. Chem. 263: 9612-9620
49. Kanda S., Kuzuya M., Ramos M. A., Koike T., Yoshino K., Ikeda S. et al. (2000) Matrix metalloproteinase and alphavbeta3 integrin-dependent vascular smooth muscle cell invasion through a type I collagen lattice. Arterioscler. Thromb. Vasc. Biol. 20: 998-1005